ETSY vs LTH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ETSY presents a concerning fundamental profile, anchored by a stable but mediocre Piotroski F-Score of 4/9 and a massive disconnect between its current price ($63.21) and its growth-based intrinsic value ($9.73). While the company maintains high gross margins, it is currently struggling with negative earnings growth (-7.10% YoY) and a poor earnings surprise track record (1/4 beats in the last year). Insider sentiment is aggressively bearish with zero buying activity and nearly $10M in sales. The negative Price/Book ratio further suggests a depleted equity base, likely due to aggressive share buybacks in a declining growth environment.
LTH exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and a valuation that sits attractively between its defensive Graham Number ($22.98) and a growth-based intrinsic value of $48.97. The company demonstrates explosive YoY earnings growth (220%) and a consistent track record of beating analyst estimates, supporting a 'Strong Buy' consensus. However, significant liquidity risks are evident in the current ratio (0.63) and quick ratio (0.40), which are compounded by bearish insider sentiment and technical trends. Overall, the growth trajectory and valuation gap outweigh short-term liquidity concerns for long-term investors.
Compare Another Pair
Related Comparisons
ETSY vs LTH: Head-to-Head Comparison
This page compares Etsy, Inc. (ETSY) and Life Time Group Holdings, Inc. (LTH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.